It is an object of the present invention to provide an anti-obesity composition and an oral administration composition that can promote the gene expression of proteins such as PGC1α and UCP1 that are involved in brown adipocytes and the energy consumption activity of the brown adipocytes, and have the effect of promoting the energy consumption activity in the brown adipocytes. The compositions of the present invention contain a tectorigenin-like substance and pinitol. The tectorigenin-like substance is preferably tectorigenin. The compositions of the present invention can suitably be used as an anti-obesity composition or an oral administration composition.

A new and improved method for preparing maxacalcitol and an intermediate therefor is provided. The method is an efficient and cost-effective process for preparing maxacalcitol and an intermediate therefor.

This TRPA1 activity inhibitor contains a compound represented by formula (I) wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each independently represent a hydrogen atom or a methyl group, and R.sup.5, R.sup.6, R.sup.7 and R.sup.8 each independently represent a hydrogen atom, a methyl group or —O—R.sup.9—OH (in the formula, R.sup.9 represents an alkylene group optionally having a substituent group), provided that at least one group of R.sup.5, R.sup.6, R.sup.7 and R.sup.8 is —O—R.sup.9—OH. ##STR00001##

This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevention of disorders, diseases or conditions responsive to the stimulation of the ghrelin receptor in a subject in need thereof. In particular, for the treatment and/or prevention of disorders responsive to the positive modulation (stimulation) of the ghrelin receptor, such as diabetes, obesity-related disorders, and, most preferably, for treating or preventing age related conditions or diseases such as by promoting appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility and treating or preventing sarcopenia by increasing net muscle mass, improving cognition (and/or treating or preventing diseases such as Azlheimer's disease, vascular dementia, Parkinson's Disease, and Huntington's disease) and treating or preventing age related hypertension.

Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol and camphor. Topical analgesic gel compositions may include from 12 to 16 wt. % menthol; from 4 to 8 wt. % camphor; from 0.1 to 2 wt. % carbomer; and 60 to 70 wt. % solvent. Topical analgesic gel compositions can have a viscosity from 60,000 to 110,000 centipoise.

The embodiments herein disclose hypoallergenic, metal surface sealant clear aerosol composition to be used on metals (specifically jewelry) to prevent skin allergies and the process of tarnishing of metal. The method of synthesizing hypoallergenic metal surface sealant clear aerosol composition comprises the following steps. The paraloid-B-48 material (10.59 wt %) is added to ethyl acetate (31.77 wt %) slowly under constant agitation. The mixture comprising paraloid-B-48 material and ethyl acetate is agitated till no lumps are present. The butyl acetate (8.47 wt %), TAXIB Plasticizer (0.70 wt %), propylene glycol monomethyl ether (PM) acetate (19.77 wt %), ethyl acetate (28.24 wt %), Chemia #46210 Lavandin (0.42 wt %) and dimethyl ether to the mixture comprising paraloid-B-48 material and ethyl acetate are added to the mixture comprising paraloid B-48 material and ethyl acetate to obtain a composition. The composition is blended at a predetermined speed to uniformly mix the components.

The embodiments herein disclose hypoallergenic, metal surface sealant clear aerosol composition to be used on metals (specifically jewelry) to prevent skin allergies and the process of tarnishing of metal. The method of synthesizing hypoallergenic metal surface sealant clear aerosol composition comprises the following steps. The paraloid-B-48 material (10.59 wt %) is added to ethyl acetate (31.77 wt %) slowly under constant agitation. The mixture comprising paraloid-B-48 material and ethyl acetate is agitated till no lumps are present. The butyl acetate (8.47 wt %), TAXIB Plasticizer (0.70 wt %), propylene glycol monomethyl ether (PM) acetate (19.77 wt %), ethyl acetate (28.24 wt %), Chemia #46210 Lavandin (0.42 wt %) and dimethyl ether to the mixture comprising paraloid-B-48 material and ethyl acetate are added to the mixture comprising paraloid B-48 material and ethyl acetate to obtain a composition. The composition is blended at a predetermined speed to uniformly mix the components.

The embodiments herein disclose hypoallergenic, metal surface sealant clear aerosol composition to be used on metals (specifically jewelry) to prevent skin allergies and the process of tarnishing of metal. The method of synthesizing hypoallergenic metal surface sealant clear aerosol composition comprises the following steps. The paraloid-B-48 material (10.59 wt %) is added to ethyl acetate (31.77 wt %) slowly under constant agitation. The mixture comprising paraloid-B-48 material and ethyl acetate is agitated till no lumps are present. The butyl acetate (8.47 wt %), TAXIB Plasticizer (0.70 wt %), propylene glycol monomethyl ether (PM) acetate (19.77 wt %), ethyl acetate (28.24 wt %), Chemia #46210 Lavandin (0.42 wt %) and dimethyl ether to the mixture comprising paraloid-B-48 material and ethyl acetate are added to the mixture comprising paraloid B-48 material and ethyl acetate to obtain a composition. The composition is blended at a predetermined speed to uniformly mix the components.

The present invention relates to a novel use of sesquiterpenoid compounds, the pharmaceutically acceptable salts thereof, or the extracts of Cyperus rotundus comprising same or the fractions thereof in the prevention or treatment of menopausal diseases. The sesquiterpenoid compound according to the present invention, the extracts of Cyperus rotundus comprising the same or fractions thereof exhibit excellent estrogenic activity or anti-allergic activity, and therefore they can be used for the prevention or treatment of menopausal diseases caused by a decline in estrogen level or by allergic diseases.

The present invention relates to a novel use of sesquiterpenoid compounds, the pharmaceutically acceptable salts thereof, or the extracts of Cyperus rotundus comprising same or the fractions thereof in the prevention or treatment of menopausal diseases. The sesquiterpenoid compound according to the present invention, the extracts of Cyperus rotundus comprising the same or fractions thereof exhibit excellent estrogenic activity or anti-allergic activity, and therefore they can be used for the prevention or treatment of menopausal diseases caused by a decline in estrogen level or by allergic diseases.